Q-omics provides the consensus-scored FUCA1 profile across patient tissues and cancer cell-line models. FUCA1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FUCA1 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, FUCA1 protein abundance shows 25,607 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KICH, and LUAD as cancer lineages where FUCA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUCA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUCA1 survival associations across molecular data types. FUCA1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUCA1 RNA expression–survival associations across cancer types. High FUCA1 expression shows unfavorable associations in LGG, but favorable associations in KIRC, LUAD, COAD, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FUCA1 RNA expression.
This table summarizes FUCA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FUCA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUCA1 shows lower tumor expression in KICH, COAD, KIRC, READ, LUSC and KIRP. The KICH box plot shows higher FUCA1 RNA expression in normal versus tumor tissue (log2 FC = −2.417, t-test p < 0.001).
This table shows molecular features associated with FUCA1 in patient tissues and cancer cell lines. In patient samples, FUCA1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FUCA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
